Squarepoint
NRIX icon

Squarepoint’s Nurix Therapeutics NRIX Stock Holding History

Squarepoint’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-224,535
Closed -$3.48M – 4797
2026
Q1 		$3.48M Buy
+224,535
New +$3.72M ﹤0.01% 1770
2025
Q4 		– Sell
-28,784
Closed -$266K – 4687
2025
Q3 		$266K Sell
28,784
-47,688
-62% -$495K ﹤0.01% 3766
2025
Q2 		$871K Sell
76,472
-8,154
-10% -$88.1K ﹤0.01% 2786
2025
Q1 		$1.01M Buy
84,626
+7,992
+10% +$134K ﹤0.01% 2653
2024
Q4 		$1.44M Buy
76,634
+9,354
+14% +$214K ﹤0.01% 2721
2024
Q3 		$1.51M Buy
67,280
+38,496
+134% +$872K ﹤0.01% 2280
2024
Q2 		$601K Buy
+28,784
New +$448K ﹤0.01% 2936
2022
Q2 		– Sell
-20,516
Closed -$287K – 3217
2022
Q1 		$287K Buy
20,516
+4,370
+27% +$77.6K ﹤0.01% 2307
2021
Q4 		$467K Buy
+16,146
New +$489K ﹤0.01% 2181
2021
Q3 		– Sell
-10,558
Closed -$280K – 3256
2021
Q2 		$280K Sell
10,558
-5,250
-33% -$154K ﹤0.01% 2589
2021
Q1 		$491K Buy
+15,808
New +$598K ﹤0.01% 2043

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's NRIX Position: Q2 2026 in Review

Squarepoint sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 224,535 shares — an estimated $3.48M sold.

Squarepoint first reported a position in NRIX in Q1 2021 and held it in 11 quarters. The position peaked at $3.48M in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Squarepoint reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 224,535 Nurix Therapeutics shares in Q2 2026, an estimated $3.48M.
  • Squarepoint first reported a position in Nurix Therapeutics in Q1 2021 and held it in 11 quarters.
  • Squarepoint's Nurix Therapeutics position peaked at $3.48M in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.